Kairos Pharma, Stock Price Prediction
| KAPA Stock | 0.74 0.01 1.33% |
Momentum 44
Sell Extended
Oversold | Overbought |
Using Kairos Pharma, hype-based prediction, you can estimate the value of Kairos Pharma, from the perspective of Kairos Pharma, response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Kairos Pharma, to buy its stock at a price that has no basis in reality. In that case, they are not buying Kairos because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Kairos Pharma, after-hype prediction price | USD 0.76 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Kairos Pharma, Basic Forecasting Models to cross-verify your projections. Kairos Pharma, After-Hype Price Prediction Density Analysis
As far as predicting the price of Kairos Pharma, at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Kairos Pharma, or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Kairos Pharma,, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Kairos Pharma, Estimiated After-Hype Price Volatility
In the context of predicting Kairos Pharma,'s stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Kairos Pharma,'s historical news coverage. Kairos Pharma,'s after-hype downside and upside margins for the prediction period are 0.04 and 6.46, respectively. We have considered Kairos Pharma,'s daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Kairos Pharma, is very risky at this time. Analysis and calculation of next after-hype price of Kairos Pharma, is based on 3 months time horizon.
Kairos Pharma, Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Kairos Pharma, is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kairos Pharma, backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Kairos Pharma,, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.47 | 5.70 | 0.00 | 0.01 | 0 Events / Month | 0 Events / Month | Uncertain |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.74 | 0.76 | 2.70 |
|
Kairos Pharma, Hype Timeline
Kairos Pharma, is now traded for 0.74. The entity stock is not elastic to its hype. The average elasticity to hype of competition is -0.01. Kairos is projected to increase in value after the next headline, with the price projected to jump to 0.76 or above. The average volatility of media hype impact on the company the price is insignificant. The price jump on the next news is forecasted to be 2.7%, whereas the daily expected return is now at -0.47%. The volatility of related hype on Kairos Pharma, is about 33529.41%, with the expected price after the next announcement by competition of 0.73. Kairos Pharma, currently holds 1.44 M in liabilities. Given the investment horizon of 90 days the next projected press release will be uncertain. Check out Kairos Pharma, Basic Forecasting Models to cross-verify your projections.Kairos Pharma, Related Hype Analysis
Having access to credible news sources related to Kairos Pharma,'s direct competition is more important than ever and may enhance your ability to predict Kairos Pharma,'s future price movements. Getting to know how Kairos Pharma,'s peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Kairos Pharma, may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| LIXT | Lixte Biotechnology Holdings | 0.00 | 0 per month | 0.00 | (0.08) | 7.16 | (7.45) | 21.12 | |
| PTHS | Pelthos Therapeutics | 0.00 | 0 per month | 0.00 | (0.06) | 8.62 | (8.07) | 28.36 | |
| LEXX | Lexaria Bioscience Corp | 0.00 | 0 per month | 0.00 | (0.11) | 8.33 | (9.68) | 46.84 | |
| CASI | CASI Pharmaceuticals | 0.00 | 0 per month | 0.00 | (0.13) | 5.88 | (7.61) | 37.34 | |
| ALLR | Allarity Therapeutics | 0.00 | 0 per month | 0.00 | (0.13) | 7.07 | (8.52) | 19.82 | |
| CLSD | Clearside Biomedical | 0.00 | 0 per month | 0.00 | (0.30) | 7.92 | (26.79) | 76.91 | |
| CING | Cingulate | 0.00 | 0 per month | 4.02 | 0.02 | 6.22 | (5.52) | 20.19 | |
| BCTX | Briacell Therapeutics Corp | 0.00 | 0 per month | 0.00 | (0.04) | 13.96 | (8.95) | 48.80 | |
| ENTO | Entero Therapeutics, | (0.17) | 10 per month | 7.81 | 0.08 | 16.50 | (17.06) | 56.75 | |
| PULM | Pulmatrix | 0.00 | 0 per month | 0.00 | (0.15) | 6.58 | (8.10) | 51.95 |
Kairos Pharma, Additional Predictive Modules
Most predictive techniques to examine Kairos price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Kairos using various technical indicators. When you analyze Kairos charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Kairos Pharma, Predictive Indicators
The successful prediction of Kairos Pharma, stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Kairos Pharma,, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Kairos Pharma, based on analysis of Kairos Pharma, hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Kairos Pharma,'s market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Kairos Pharma,'s related companies.
Story Coverage note for Kairos Pharma,
The number of cover stories for Kairos Pharma, depends on current market conditions and Kairos Pharma,'s risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Kairos Pharma, is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Kairos Pharma,'s long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Kairos Pharma, Short Properties
Kairos Pharma,'s future price predictability will typically decrease when Kairos Pharma,'s long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Kairos Pharma, often depends not only on the future outlook of the potential Kairos Pharma,'s investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Kairos Pharma,'s indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 11.4 M | |
| Cash And Short Term Investments | 1.3 M |
Complementary Tools for Kairos Stock analysis
When running Kairos Pharma,'s price analysis, check to measure Kairos Pharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kairos Pharma, is operating at the current time. Most of Kairos Pharma,'s value examination focuses on studying past and present price action to predict the probability of Kairos Pharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kairos Pharma,'s price. Additionally, you may evaluate how the addition of Kairos Pharma, to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |